1.85) and 0.67 (95% CI 0.50-0.91) respectively. Pooled odds ratio of progression-free survival in 5 yrs and 10 yrs were 0.39 (95% CI 0.29-0.54) and 0.51 (95% CI 0.34-0.76) respectively. Results demonstrate a significant survival benefit in giving pembrolizumab with chemo Conclusion: Pembrolizumab plus chemotherapy improved overall survival and progression-free survival in patients with PD-L1 positive advanced NSCLC. We encourage using this regimen as first line treatment. Keywords: Pembrolizumab, Advanced NSCLC, PD-L1 Positive This study aims to analyze the changes of PD-L1, PD-L2 in lung cancer tissues and the changes of TILs surrounding the tumor before and after neoadjuvant chemotherapy, in order to provide a theoretical basis for relevant clinical studies. Method: Tumor samples were obtained from 26 patients who confirmed primary lung cancer before and after NAC in the First Hospital of Jilin University. The expression of PD-L1, PD-L2 in lung cancer specimens and the TILs around the tumor were assessed by IHC. 5%, 10%, 20%, 30%, 50% expression thresholds were used to define PD-L1, PD-L2 positive status, respectively. We analyze the changes of PD-L1 and PD-L2 in lung cancer tissues before and after NAC, the correlation between the changes of PD-L1 in lung cancer tissues and tumor shrink rate, the interval from the end of NAC to operation, pathological type, gender and smoking status. Of 16 patients, the changes of TILs around the tumor before and after NAC were also evaluated. P<0.05 was considered statistically significant. Results: 1. When using 5%, 10%, and 20% as expression threshold, 65.4%, 53.8%, and 42.3% were found to be PD-L1 positive prior to NAC, and 92.3%, 80.8%, 69.2% expressed positively after NAC, PD-L1 was up-regulated after NAC (P¼0.008, P¼0.016, P¼0.016 ), however, there were no obviously statistical significance about the expression of PD-L1 when using 30%, 50% expression threshold (P＞0.05 ). 2. The expression of PD-L2 were not show any statistical significance before and after NAC（P>0.05 ). 3. Of 16 patients, the expression of CD4 + , CD8 + , and CD28 + lymphocytes increased after NAC compared with that before NAC (P¼0.014, P¼0.038, P¼0.021), whereas the change of CD56 + lymphocytes was not statistical significant (P> 0.05). 4. There were no significant difference between the changes of PD-L1 and tumor shrink rate, interval from the end of NAC to operation, pathological type, gender and smoking status (P>0.05 ). Conclusion: 1. The expression of PD-L1 in lung cancer tissues were increased after NAC when the expression thresholds were 5%, 10%, and 20%. 2. The expression of CD4+, CD8+ and CD28+ lymphocytes were increased after NAC. 3. No correlation exists between the variation of PD-L1 and tumor shrink rate, interval from the end of NAC to operation, pathological type, gender and smoking status. Background: Immunotherapy (PD-1/PD-L1 inhibitors) has been shown to be less effective in non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. However, little is known regarding its performance in real-world. The efficacy of immunotherapy might be different in patients with different mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Herein, we carried out a retrospective study to describe real clinical outcomes when using PD-1/PD-L1 inhibitors to treat NSCLC patients with EGFR mutation. Method: We retrospectively identified 27 patients with EGFR mutation-positive NSCLC who were treated with PD-1/PD-L1 inhibitors between January 2017 and April 2018. Results: Of 27 patients included in our study, 40.7% (n¼11) harbored EGFR ex19del, 51.9% (n¼14) harbored EGFR L858R, 3.7% (n¼1) harbored EGFR G719X and 3.7 % (n¼1) harbored EGFR ex20S768I. A total of 26 patients were treated with PD-1/PD-L1 inhibitors after disease progression during treatment with at least one EGFR-TKI and only one patient was EGFR-TKI naïve. Median progression-free survival (PFS) was 2.2 months (95% CI, 1.2 to 3.2) and 1.4 months (95% CI, 1.4 to 1.5) for patients with EGFR ex19del and patients with EGFR L858R, respectively (P¼0.174). Median PFS was 2.8 months (95% CI, 1.6 to 3.9), 1.4 months (95% CI, 1.3 to 1.5) and 2.6 (95% CI, 0.9 to 4.4) for patients with EGFR-TKIs exposure time of <6 months, 6 -12 months and >12months, respectively (P¼0.894). Next, we associated T790M status with efficacy of immunotherapy in 16 patients who performed repeat detection on either tumor biopsies or blood samples after developing resistance to EGFR TKIs, and found median PFS was 2.8 (95% CI, 2.1 to 3.4) and 1.4 months (95% CI, 1.2 to 1.6) for T790M-negative and T790M-positive patients, respectively (P¼ 0.097). Conclusion: We discovered that different types of EGFR mutation and different EGFR-TKIs exposure time were not associated with the efficacy of the immunotherapy in NSCLC patients with EGFR mutation. In addition, patients harboring acquired T790M mutation after EGFR-TKI treatment are more likely to have shorter PFS of immunotherapy.
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Effects of Neoadjuvant Chemotherapy on the Expression of PD-L1 and Tumor Infiltrating Lymphocytes in Lung Cancer Tissues W. Sun, 1 K. Ma 2 1 Jilin Province Oncology Hospital, Changchun/CN, 2 First Hospital of Jilin University, Changchun/CN Background: Immune checkpoints PD-1 and its ligand PD-L1, PD-L2 pathways can mediate negative synergistic stimulation signals. Immunotherapy combined with chemotherapy can increase the objective response rate of cancer patients. This study aims to analyze the changes of PD-L1, PD-L2 in lung cancer tissues and the changes of TILs surrounding the tumor before and after neoadjuvant chemotherapy, in order to provide a theoretical basis for relevant clinical studies. Method: Tumor samples were obtained from 26 patients who confirmed primary lung cancer before and after NAC in the First Hospital of Jilin University. The expression of PD-L1, PD-L2 in lung cancer specimens and the TILs around the tumor were assessed by IHC. 5%, 10%, 20%, 30%, 50% expression thresholds were used to define PD-L1, PD-L2 positive status, respectively. We analyze the changes of PD-L1 and PD-L2 in lung cancer tissues before and after NAC, the correlation between the changes of PD-L1 in lung cancer tissues and tumor shrink rate, the interval from the end of NAC to operation, pathological type, gender and smoking status. Of 16 patients, the changes of TILs around the tumor before and after NAC were also evaluated. P<0.05 was considered statistically significant. Results: 1. When using 5%, 10%, and 20% as expression threshold, 65.4%, 53.8%, and 42.3% were found to be PD-L1 positive prior to NAC, and 92.3%, 80.8%, 69.2% expressed positively after NAC, PD-L1 was up-regulated after NAC (P¼0.008, P¼0.016, P¼0.016 ), however, there were no obviously statistical significance about the expression of PD-L1 when using 30%, 50% expression threshold (P＞0.05 ). 2. The expression of PD-L2 were not show any statistical significance before and after NAC（P>0.05 ). 3. Of 16 patients, the expression of CD4 + , CD8 + , and CD28 + lymphocytes increased after NAC compared with that before NAC (P¼0.014, P¼0.038, P¼0.021), whereas the change of CD56 + lymphocytes was not statistical significant (P> 0.05). 4. There were no significant difference between the changes of PD-L1 and tumor shrink rate, interval from the end of NAC to operation, pathological type, gender and smoking status (P>0.05 ). Conclusion: 1. The expression of PD-L1 in lung cancer tissues were increased after NAC when the expression thresholds were 5%, 10%, and 20%. Background: Immunotherapy (PD-1/PD-L1 inhibitors) has been shown to be less effective in non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. However, little is known regarding its performance in real-world. The efficacy of immunotherapy might be different in patients with different mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Herein, we carried out a retrospective study to describe real clinical outcomes when using PD-1/PD-L1 inhibitors to treat NSCLC patients with EGFR mutation. Method: We retrospectively identified 27 patients with EGFR mutation-positive NSCLC who were treated with PD-1/PD-L1 inhibitors between January 2017 and April 2018. Results: Of 27 patients included in our study, 40.7% (n¼11) harbored EGFR ex19del, 51.9% (n¼14) harbored EGFR L858R, 3.7% (n¼1) harbored EGFR G719X and 3.7 % (n¼1) harbored EGFR ex20S768I. A total of 26 patients were treated with PD-1/PD-L1 inhibitors after disease progression during treatment with at least one EGFR-TKI and only one patient was EGFR-TKI naïve. Median progression-free survival (PFS) was 2.2 months (95% CI, 1.2 to 3.2) and 1.4 months (95% CI, 1.4 to 1.5) for patients with EGFR ex19del and patients with EGFR L858R, respectively (P¼0.174). Median PFS was 2.8 months (95% CI, 1.6 to 3.9), 1.4 months (95% CI, 1.3 to 1.5) and 2.6 (95% CI, 0.9 to 4.4) for patients with EGFR-TKIs exposure time of <6 months, 6 -12 months and >12months, respectively (P¼0.894). Next, we associated T790M status with efficacy of immunotherapy in 16 patients who performed repeat detection on either tumor biopsies or blood samples after developing resistance to EGFR TKIs, and found median PFS was 2.8 (95% CI, 2.1 to 3.4) and 1.4 months (95% CI, 1.2 to 1.6) for T790M-negative and T790M-positive patients, respectively (P¼ 0.097). Conclusion: We discovered that different types of EGFR mutation and different EGFR-TKIs exposure time were not associated with the efficacy of the immunotherapy in NSCLC patients with EGFR mutation. In addition, patients harboring acquired T790M mutation after EGFR-TKI treatment are more likely to have shorter PFS of immunotherapy. Keywords: immunotherapy, epidermal growth factor receptor, T790M, non-small-cell lung cancer
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